title: Free fatty acids increase hepatic glycogen content in obese males.
abstract: Obesity is associated with increased hepatic glycogen content. In vivo and in vitro data suggest that plasma free fatty acids (FFA) may cause this increase. In this study we investigated the effect of physiological plasma FFA levels on hepatic glycogen metabolism by studying intrahepatic glucose pathways in lean and obese subjects. Six lean and 6 obese males were studied twice during a 16- to 22-hour fast, once with and once without acipimox, an inhibitor of lipolysis. Intrahepatic glucose fluxes were measured by infusion of [2-(13C1)]glycerol, [1-(2H1)]galactose, and [U-(13C6)]glucose. Acetaminophen was administered as a glucuronate probe. In both lean and obese control studies, plasma FFA levels increased progressively, whereas acipimox completely suppressed plasma FFA levels for the whole study period. In lean males glycogenolysis did not change in the acipimox study, but decreased in the control study (P < .01). In lean males, neither glycogen synthesis, glycogen synthesis retained as glycogen, nor glycogen balance differed between control and acipimox studies. In obese males glycogenolysis did not change in the acipimox study, but decreased in the control study (P < .01). Glycogen synthesis did not change in either study. Glycogen synthesis retained as glycogen did not change in acipimox study, but increased in the control study (P = .03). Glycogen balance did not change in the acipimox study, but increased in the control study (P < .01). This study demonstrates that in obese males physiological levels of FFA contribute to the retention of hepatic glycogen during short-term fasting by inhibiting breakdown of glycogen and increasing glycogen synthesis retained as glycogen, whereas in lean males this effect was absent due to unaltered glycogen synthesis retained as glycogen.
authors.affiliation: Metabolism Research Unit, Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Allick
authors.forename: F
authors.initials: F
authors.lastname: Sprangers
authors.forename: G J
authors.initials: GJ
authors.lastname: Weverling
authors.forename: M T
authors.initials: MT
authors.lastname: Ackermans
authors.forename: A J
authors.initials: AJ
authors.lastname: Meijer
authors.forename: J A
authors.initials: JA
authors.lastname: Romijn
authors.forename: E
authors.initials: E
authors.lastname: Endert
authors.forename: P H
authors.initials: PH
authors.lastname: Bisschop
authors.forename: H P
authors.initials: HP
authors.lastname: Sauerwein
mesh_terms: D000328:Adult; D002096:C-Peptide / Q000097:blood; D005215:Fasting / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000494:pharmacology*; D008401:Gas Chromatography-Mass Spectrometry; D005943:Gluconeogenesis / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D006728:Hormones / Q000097:blood; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism*; D011719:Pyrazines / Q000494:pharmacology; D013268:Stimulation, Chemical
chemical_list: D002096:C-Peptide; D005230:Fatty Acids, Nonesterified; D006728:Hormones; D000960:Hypolipidemic Agents; D007328:Insulin; D008112:Liver Glycogen; D011719:Pyrazines; D005947:Glucose; C027696:acipimox